INMBNasdaqBiological Products, (No Diagnostic Substances)US GAAP · USD

Inmune Bio, Inc.

Inmune Bio, Inc. is a clinical-stage biotechnology company developing immunology-based therapies for inflammatory, neurodegenerative, and rare disease indications. Its pipeline includes CORDStrom and XPro, with the company still pre-commercial and dependent on clinical progress, regulatory milestones, and external financing.

Kysy yhtiöstä
Liikevaihto0,1milj. USD
+257,1 %v/v
Liikevoitto (EBIT)−47,4milj. USD
−11,1 %v/v
EBIT-marginaali−94 766,0%
+209 769,7 %-yks.v/v
Nettotulos−45,9milj. USD
−9,2 %v/v
Vapaa kassavirta−23,6milj. USD
+29,2 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−50−40−30−20−10010milj. USD2020: 0,01 milj. USD2020: EBIT −12 milj. USD20202021: 0,18 milj. USD2021: EBIT −29 milj. USD20212022: 0,37 milj. USD2022: EBIT −26 milj. USD20222023: 0,16 milj. USD2023: EBIT −30 milj. USD20232024: 0,01 milj. USD2024: EBIT −43 milj. USD20242025: 0,05 milj. USD2025: EBIT −47 milj. USD20250,05−47
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
CORDStrom60 %

Cell therapy program focused on RDEB and related rare disease treatment pathways.

XPro25 %

Anti-inflammatory biologic program aimed at neuroinflammation and CNS-related disorders.

Collaborations and licensing10 %

Revenue from license agreements, data access arrangements, and related milestones.

Other research programs5 %

Earlier-stage discovery and preclinical work supporting future pipeline expansion.

Asiakkaat

The company does not sell broadly to end consumers; its economic customers are patients, physicians, hospitals, and regulators that determine whether its therapies can be adopted and reimbursed. In the near term, value is created through clinical trial enrollment, licensing arrangements, and potential future commercialization of approved biologic products. Academic and hospital partners also matter because they generate clinical data and support development milestones.

Rare disease patients and caregivers

Patients with RDEB and other severe unmet-need conditions who would use CORDStrom if approved.

Clinical investigators and hospitals

Trial sites that enroll patients, administer study treatment, and generate efficacy/safety data.

Regulatory agencies

FDA, EMA, and MHRA review the company’s CMC, safety, and efficacy packages and determine approval.

Strategic partners and licensors

Third parties that may fund, license, or commercialize programs or provide clinical data access.

Strategia

The company’s strategy is to advance its lead programs through clinical development, secure regulatory designations, and convert trial data into approval and commercialization opportunities. It is also using collaborations, licensing, and capital raises to fund operations while it remains pre-revenue and cash-consuming. The Mission EB data license and FDA orphan/rare pediatric designations show a focus on de-risking CORDStrom and improving its partnering and approval profile.

Advance CORDStrom toward marketing authorizationLyhyt aikaväli

Approval would unlock commercialization, exclusivity benefits, and potential PRV value.

Use external clinical data and partnershipsLyhyt aikaväli

Licensing and collaborations can accelerate development and reduce internal spend.

Fund operations through equity and strategic financingLyhyt aikaväli

The company has recurring losses and substantial doubt about going concern.

Build clinical evidence for XPro and other programsKeskipitkä aikaväli

Pipeline breadth can create future value beyond a single asset.

Maantiede

Inmune Bio is headquartered in the United States, but a meaningful part of its research and development spending occurs in Australia and the United Kingdom. The company also references interactions with U.S., U.K., and European regulators, reflecting a development footprint that is broader than its current revenue base. Foreign currency exposure matters because operating costs are incurred in pounds sterling and Australian dollars while reporting in U.S. dollars.

Riskit

Inmune Bio faces classic clinical-stage biotech risks: trial failure, regulatory delay, and uncertainty around whether its programs can reach approval and commercialization. The company also has a going-concern profile, with recurring losses and dependence on equity financing, while foreign-currency exposure and third-party manufacturing/CRO reliance can add volatility to costs and execution.

Järjestetty vakavuuden mukaan
Going concern and liquidity shortfallKriittinen

The company has recurring net losses and negative cash flows and may need additional capital before commercialization.

Kohdistuu: Cash runway and ability to fund clinical development

Clinical development failureKorkea

Pipeline value depends on positive trial outcomes for CORDStrom and XPro.

Kohdistuu: Lead asset approval probability

Regulatory and CMC execution riskKorkea

FDA/EMA/MHRA feedback can require additional studies, manufacturing changes, or delays.

Kohdistuu: Approval timing and development cost

Foreign exchange volatilityKeskitaso

R&D is incurred in Australia and the United Kingdom, creating translation and transaction exposure.

Kohdistuu: Operating expenses and foreign subsidiary balances

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition on license agreements

Small revenue amounts appear tied to a terminated license and prior asset sales, so timing and contract terms matter.

Vaikutus: Can create lumpy quarterly revenue and comparability issues

Impairment of acquired in-process R&D

The company recorded a large impairment charge, indicating valuation sensitivity for development-stage assets.

Vaikutus: Non-cash charge can materially widen reported losses

Stock-based compensation

Equity awards are a recurring compensation tool for a cash-constrained biotech.

Vaikutus: Raises operating expenses and affects loss metrics

Foreign currency translation

R&D spending in pounds sterling and Australian dollars creates exchange-rate effects.

Vaikutus: Moves expenses, assets, and liabilities in reported U.S. dollars

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

IN8bio, Inc

INAB · Biological Products, (No Diagnostic Substances)

Evommune, Inc.

EVMN · Pharmaceutical Preparations

IO Biotech, Inc.

IOBTQ · Pharmaceutical Preparations

Mustang Bio, Inc

MBIO · Pharmaceutical Preparations

ImageneBio, Inc.

IMA · Biological Products, (No Diagnostic Substances)

iBio, Inc.

IBIO · Pharmaceutical Preparations

Päivitetty: 24.9.2026